MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Incyte Corp

Открыт

СекторЗдравоохранение

58.63 0.36

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

57.77

Макс.

59.02

Ключевые показатели

By Trading Economics

Доход

95M

201M

Продажи

39M

1.2B

P/E

Средняя по отрасли

378.667

57.333

Прибыль на акцию

1.43

Рентабельность продаж

17.071

Сотрудники

2,617

EBITDA

145M

337M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+25.27% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

29 апр. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-5.4B

11B

Предыдущая цена открытия

58.27

Предыдущая цена закрытия

58.63

Техническая оценка

By Trading Central

Уверенность

Strong Bullish Evidence

Incyte Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 апр. 2025 г., 23:54 UTC

Популярные акции

Stocks to Watch: Alphabet, Intel, AppFolio

24 апр. 2025 г., 23:51 UTC

Обсуждения рынка

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 апр. 2025 г., 23:46 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

24 апр. 2025 г., 23:46 UTC

Обсуждения рынка

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 апр. 2025 г., 23:37 UTC

Главные новости

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 апр. 2025 г., 23:36 UTC

Главные новости

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 апр. 2025 г., 23:13 UTC

Главные новости
Отчет

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 апр. 2025 г., 23:09 UTC

Главные новости

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 апр. 2025 г., 23:02 UTC

Приобретения, слияния, поглощения

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 апр. 2025 г., 23:02 UTC

Приобретения, слияния, поглощения

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 апр. 2025 г., 22:51 UTC

Главные новости
Приобретения, слияния, поглощения

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 апр. 2025 г., 22:48 UTC

Главные новости

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 апр. 2025 г., 22:47 UTC

Обсуждения рынка

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 апр. 2025 г., 22:38 UTC

Обсуждения рынка
Отчет

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 апр. 2025 г., 22:24 UTC

Отчет

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 апр. 2025 г., 22:24 UTC

Отчет

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 апр. 2025 г., 22:24 UTC

Обсуждения рынка
Отчет

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 апр. 2025 г., 22:23 UTC

Отчет

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 апр. 2025 г., 22:11 UTC

Обсуждения рынка
Отчет

Global Equities Roundup: Market Talk

24 апр. 2025 г., 22:11 UTC

Обсуждения рынка
Отчет

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 апр. 2025 г., 22:09 UTC

Главные новости
Отчет

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 апр. 2025 г., 22:00 UTC

Обсуждения рынка
Отчет

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 апр. 2025 г., 21:39 UTC

Главные новости

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 апр. 2025 г., 21:24 UTC

Главные новости
Отчет

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 апр. 2025 г., 21:24 UTC

Главные новости
Отчет

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 апр. 2025 г., 21:23 UTC

Главные новости
Отчет

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 апр. 2025 г., 21:04 UTC

Отчет

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 апр. 2025 г., 21:03 UTC

Отчет

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 апр. 2025 г., 21:03 UTC

Отчет

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 апр. 2025 г., 21:02 UTC

Отчет

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Сравнение c конкурентами

Изменение цены

Incyte Corp Прогноз

Целевая цена

By TipRanks

25.27% рост

Прогноз на 12 месяцев

Средняя 73.87 USD  25.27%

Максимум 92 USD

Минимум 52 USD

Основано на мнении 18 аналитиков Wall Street, спрогнозировавших целевые цены для Incyte Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

18 ratings

6

Покупка

11

Удержание

1

Продажа

Техническая оценка

By Trading Central

58.33 / 59.22Поддержка и Сопротивление

Краткосрочная

Strong Bullish Evidence

Среднесрочная

Strong Bearish Evidence

Долгосрочная

Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation